Personalis Inc 's Cash & cash equivalent grew by 19.38 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Personalis Inc 's Quick Ratio to 6, above Personalis Inc average Quick Ratio.

Within Medical Laboratories industry 7 other companies have achieved higher Quick Ratio than Personalis Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 526 to 634.

Explain Quick Ratio?
How much Cash & cash equivalents PSNL�s has?
What are PSNL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PSNL Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	46.22 %	30.62 %	27.32 %	-0.71 %	-7.06 %
Y / Y Cash & cash equivalent Change	60.72 %	25.6 %	29.7 %	4.78 %	99.18 %
Quick Ratio MRQ	6	5.97	6.05	4.16	5.46
PSNL's Total Ranking	# 634	# 526	# 283	# 607	# 245
Seq. Current Liabilities Change	18.8 %	-1.48 %	9.61 %	13.97 %	6.13 %
Seq. Cash & cash equivalent Change	19.38 %	-2.81 %	59.42 %	-13.11 %	-6.71 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 8
Healthcare Sector	# 264
Overall Market	# 634

Quick Ratio Statistics
High	Average	Low
11.51	5.57	1.26
(Sep 30 2021)		(Dec 31 2018)

Financial Statements
Personalis Inc 's Current Liabilities	$ 46 Millions	Visit PSNL's Balance sheet
Personalis Inc 's Cash & cash equivalent	$ 278 Millions	Visit PSNL's Balance sheet
Source of PSNL's Sales		Visit PSNL's Sales by Geography

Cumulative Personalis Inc 's Quick Ratio

PSNL's Quick Ratio for the trailling 12 Months

PSNL Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	24.82 %	11.39 %	3.27 %	-16.76 %	-14.42 %
Y / Y Cash & cash equivalent TTM Growth	31.2 %	32.53 %	46.64 %	57.75 %	64.8 %
Quick Ratio TTM	5.6	5.44	5.45	5.39	5.32
Total Ranking TTM	# 3880	# 3610	# 2764	# 2754	# 2508
Seq. Current Liabilities TTM Growth	10 %	6.66 %	6.6 %	-0.2 %	-1.83 %
Seq. Cash & cash equivalent TTM Growth	13.2 %	6.34 %	7.91 %	1 %	14.35 %

Quick ratio ranking by company, industry and sector >> Back to PSNL Financial Strength Comparisons >> Go to Compare PSNL Quick Ratio to its Competitors

On the trailing twelve months basis PSNL Cash & cash equivalent soared by 60.72 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Personalis Inc 's Quick Ratio to 5.6, above PSNL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 34 other companies have achieved higher Quick Ratio than Personalis Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3610 to 3880.

Explain Quick Ratio?
How much Cash & cash equivalents PSNL�s has?
What are PSNL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 35
Healthcare Sector	# 885
Within the Market	# 3880

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.01	2.15	1.11
(Dec 31 2021)		(Jun 30 2020)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Aclarion Inc	15.50	$ 16.285 Millions	$ 1.051 Millions
Miragen Therapeutics Inc	12.67	$ 981.530 Millions	$ 77.484 Millions
Maxcyte inc	10.68	$ 105.690 Millions	$ 9.895 Millions
Grail Inc	10.29	$ 859.755 Millions	$ 83.542 Millions
Absci Corp	10.12	$ 201.142 Millions	$ 19.878 Millions
Billiontoone Inc	9.85	$ 548.628 Millions	$ 55.725 Millions
Celcuity Inc	8.68	$ 754.000 Millions	$ 86.873 Millions
Veracyte Inc	7.76	$ 487.046 Millions	$ 62.736 Millions
Personalis Inc	6.00	$ 278.411 Millions	$ 46.385 Millions
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions
Natera Inc	1.97	$ 1,091.502 Millions	$ 553.200 Millions
Biodesix Inc	1.96	$ 29.996 Millions	$ 15.291 Millions
Sera Prognostics Inc	1.91	$ 46.445 Millions	$ 24.356 Millions
Exagen Inc	1.83	$ 24.588 Millions	$ 13.457 Millions

Date modified: 2026-09-26T07:36:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.